NCT00134043View on ClinicalTrials.gov

Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Insular Thyroid CancerRecurrent Thyroid CancerStage II Follicular Thyroid CancerStage II Papillary Thyroid CancerStage IV Follicular Thyroid CancerStage IV Papillary Thyroid CancerThyroid Gland Medullary Carcinoma
Interventions
DRUG

vorinostat

Given orally

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00134043 - Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer | Biotech Hunter | Biotech Hunter